Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 2,160,516 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 2,160,516 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director directly owned 428,946 shares in the company, valued at $10,723,650. This represents a 83.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Up 1.8%

Shares of DYN traded up $0.45 during midday trading on Monday, hitting $26.15. The company had a trading volume of 1,317,571 shares, compared to its average volume of 2,103,342. Dyne Therapeutics, Inc. has a 1 year low of $11.65 and a 1 year high of $27.31. The firm has a market capitalization of $4.88 billion, a P/E ratio of -7.85 and a beta of 1.07. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The company’s 50-day simple moving average is $22.83 and its 200-day simple moving average is $19.50.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.37 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently bought and sold shares of DYN. AQR Capital Management LLC acquired a new position in Dyne Therapeutics during the first quarter worth approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after acquiring an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after acquiring an additional 366,183 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Dyne Therapeutics in the 1st quarter valued at $157,000. Finally, Creative Planning raised its position in Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after purchasing an additional 2,797 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on DYN shares. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 15th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday. Sanford C. Bernstein boosted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Finally, Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $34.42.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.